207 related articles for article (PubMed ID: 11715002)
1. Functional significance of PMM2 mutations in mildly affected patients with congenital disorders of glycosylation Ia.
Westphal V; Peterson S; Patterson M; Tournay A; Blumenthal A; Treacy EP; Freeze HH
Genet Med; 2001; 3(6):393-8. PubMed ID: 11715002
[TBL] [Abstract][Full Text] [Related]
2. High residual activity of PMM2 in patients' fibroblasts: possible pitfall in the diagnosis of CDG-Ia (phosphomannomutase deficiency).
Grünewald S; Schollen E; Van Schaftingen E; Jaeken J; Matthijs G
Am J Hum Genet; 2001 Feb; 68(2):347-54. PubMed ID: 11156536
[TBL] [Abstract][Full Text] [Related]
3. Identification of four novel PMM2 mutations in congenital disorders of glycosylation (CDG) Ia French patients.
Vuillaumier-Barrot S; Hetet G; Barnier A; Dupré T; Cuer M; de Lonlay P; Cormier-Daire V; Durand G; Grandchamp B; Seta N
J Med Genet; 2000 Aug; 37(8):579-80. PubMed ID: 10922383
[TBL] [Abstract][Full Text] [Related]
4. A frequent mild mutation in ALG6 may exacerbate the clinical severity of patients with congenital disorder of glycosylation Ia (CDG-Ia) caused by phosphomannomutase deficiency.
Westphal V; Kjaergaard S; Schollen E; Martens K; Grunewald S; Schwartz M; Matthijs G; Freeze HH
Hum Mol Genet; 2002 Mar; 11(5):599-604. PubMed ID: 11875054
[TBL] [Abstract][Full Text] [Related]
5. Scandinavian CDG-Ia patients: genotype/phenotype correlation and geographic origin of founder mutations.
Erlandson A; Bjursell C; Stibler H; Kristiansson B; Wahlström J; Martinsson T
Hum Genet; 2001 May; 108(5):359-67. PubMed ID: 11409861
[TBL] [Abstract][Full Text] [Related]
6. PMM2-CDG: phenotype and genotype in four affected family members.
Bortot B; Cosentini D; Faletra F; Biffi S; De Martino E; Carrozzi M; Severini GM
Gene; 2013 Dec; 531(2):506-9. PubMed ID: 23988505
[TBL] [Abstract][Full Text] [Related]
7. Neurological presentation of a congenital disorder of glycosylation CDG-Ia: implications for diagnosis and genetic counseling.
Drouin-Garraud V; Belgrand M; Grünewald S; Seta N; Dacher JN; Hénocq A; Matthijs G; Cormier-Daire V; Frébourg T; Saugier-Veber P
Am J Med Genet; 2001 Jun; 101(1):46-9. PubMed ID: 11343337
[TBL] [Abstract][Full Text] [Related]
8. Yeast Models of Phosphomannomutase 2 Deficiency, a Congenital Disorder of Glycosylation.
Lao JP; DiPrimio N; Prangley M; Sam FS; Mast JD; Perlstein EO
G3 (Bethesda); 2019 Feb; 9(2):413-423. PubMed ID: 30530630
[TBL] [Abstract][Full Text] [Related]
9. Functional analysis of novel mutations in a congenital disorder of glycosylation Ia patient with mixed Asian ancestry.
Westphal V; Enns GM; McCracken MF; Freeze HH
Mol Genet Metab; 2001 May; 73(1):71-6. PubMed ID: 11350185
[TBL] [Abstract][Full Text] [Related]
10. A deletion-insertion mutation in the phosphomannomutase 2 gene in an African American patient with congenital disorders of glycosylation-Ia.
Tayebi N; Andrews DQ; Park JK; Orvisky E; McReynolds J; Sidransky E; Krasnewich DM
Am J Med Genet; 2002 Mar; 108(3):241-6. PubMed ID: 11891694
[TBL] [Abstract][Full Text] [Related]
11. The Effects of PMM2-CDG-Causing Mutations on the Folding, Activity, and Stability of the PMM2 Protein.
Yuste-Checa P; Gámez A; Brasil S; Desviat LR; Ugarte M; Pérez-Cerdá C; Pérez B
Hum Mutat; 2015 Sep; 36(9):851-60. PubMed ID: 26014514
[TBL] [Abstract][Full Text] [Related]
12. Clinical, laboratory and molecular findings and long-term follow-up data in 96 French patients with PMM2-CDG (phosphomannomutase 2-congenital disorder of glycosylation) and review of the literature.
Schiff M; Roda C; Monin ML; Arion A; Barth M; Bednarek N; Bidet M; Bloch C; Boddaert N; Borgel D; Brassier A; Brice A; Bruneel A; Buissonnière R; Chabrol B; Chevalier MC; Cormier-Daire V; De Barace C; De Maistre E; De Saint-Martin A; Dorison N; Drouin-Garraud V; Dupré T; Echenne B; Edery P; Feillet F; Fontan I; Francannet C; Labarthe F; Gitiaux C; Héron D; Hully M; Lamoureux S; Martin-Coignard D; Mignot C; Morin G; Pascreau T; Pincemaille O; Polak M; Roubertie A; Thauvin-Robinet C; Toutain A; Viot G; Vuillaumier-Barrot S; Seta N; De Lonlay P
J Med Genet; 2017 Dec; 54(12):843-851. PubMed ID: 28954837
[TBL] [Abstract][Full Text] [Related]
13. A nationwide survey of PMM2-CDG in Italy: high frequency of a mild neurological variant associated with the L32R mutation.
Barone R; Carrozzi M; Parini R; Battini R; Martinelli D; Elia M; Spada M; Lilliu F; Ciana G; Burlina A; Leuzzi V; Leoni M; Sturiale L; Matthijs G; Jaeken J; Di Rocco M; Garozzo D; Fiumara A
J Neurol; 2015 Jan; 262(1):154-64. PubMed ID: 25355454
[TBL] [Abstract][Full Text] [Related]
14. Expression analysis revealing destabilizing mutations in phosphomannomutase 2 deficiency (PMM2-CDG): expression analysis of PMM2-CDG mutations.
Vega AI; Pérez-Cerdá C; Abia D; Gámez A; Briones P; Artuch R; Desviat LR; Ugarte M; Pérez B
J Inherit Metab Dis; 2011 Aug; 34(4):929-39. PubMed ID: 21541725
[TBL] [Abstract][Full Text] [Related]
15. A mouse model of a human congenital disorder of glycosylation caused by loss of PMM2.
Chan B; Clasquin M; Smolen GA; Histen G; Powe J; Chen Y; Lin Z; Lu C; Liu Y; Cang Y; Yan Z; Xia Y; Thompson R; Singleton C; Dorsch M; Silverman L; Su SM; Freeze HH; Jin S
Hum Mol Genet; 2016 Jun; 25(11):2182-2193. PubMed ID: 27053713
[TBL] [Abstract][Full Text] [Related]
16. The Analysis of Variants in the General Population Reveals That
Citro V; Cimmaruta C; Monticelli M; Riccio G; Hay Mele B; Cubellis MV; Andreotti G
Int J Mol Sci; 2018 Jul; 19(8):. PubMed ID: 30061496
[TBL] [Abstract][Full Text] [Related]
17. [Congenital disorder of glycosylation type Ia (CDG Ia) - underdiagnosed entity?].
Sätilä H; Kuusela AL; Pietilä K; Niinikoski H; Keskinen P
Duodecim; 2016; 132(3):253-9. PubMed ID: 26951030
[TBL] [Abstract][Full Text] [Related]
18. A zebrafish model of PMM2-CDG reveals altered neurogenesis and a substrate-accumulation mechanism for N-linked glycosylation deficiency.
Cline A; Gao N; Flanagan-Steet H; Sharma V; Rosa S; Sonon R; Azadi P; Sadler KC; Freeze HH; Lehrman MA; Steet R
Mol Biol Cell; 2012 Nov; 23(21):4175-87. PubMed ID: 22956764
[TBL] [Abstract][Full Text] [Related]
19. Phosphomannose isomerase inhibitors improve N-glycosylation in selected phosphomannomutase-deficient fibroblasts.
Sharma V; Ichikawa M; He P; Scott DA; Bravo Y; Dahl R; Ng BG; Cosford ND; Freeze HH
J Biol Chem; 2011 Nov; 286(45):39431-8. PubMed ID: 21949237
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological Chaperoning: A Potential Treatment for PMM2-CDG.
Yuste-Checa P; Brasil S; Gámez A; Underhaug J; Desviat LR; Ugarte M; Pérez-Cerdá C; Martinez A; Pérez B
Hum Mutat; 2017 Feb; 38(2):160-168. PubMed ID: 27774737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
